Mesalamine Rectal Therapy in Patients with Ileostomy
Rationale for Not Using Rectal Mesalamine in Ileostomy Patients
- The European Crohn’s and Colitis Organisation recommends against using rectal mesalamine therapy in patients with an ileostomy as it would be ineffective due to the surgical diversion of intestinal contents away from the rectum 1, 2
- An ileostomy surgically diverts intestinal contents through an opening in the abdominal wall, bypassing the colon and rectum completely 3
- Rectal mesalamine formulations are designed to deliver the active medication directly to the inflamed rectal and colonic mucosa, but in patients with an ileostomy, the fecal stream no longer passes through the rectum, making topical therapy ineffective 1, 2, 3
Therapeutic Considerations for Ulcerative Colitis Patients with Ileostomy
- The American Gastroenterological Association recommends that for patients with an ileostomy who have remaining rectal tissue with active inflammation, systemic therapy would be more appropriate than rectal formulations 4, 5
- Oral mesalamine at standard doses is the preferred approach for mild-moderate inflammation in any remaining colorectal tissue 5, 6
- For moderate-to-severe inflammation in remaining rectal tissue, systemic corticosteroids, immunomodulators, or biologics may be necessary 5, 7
Understanding Rectal Mesalamine Delivery
- Rectal mesalamine formulations are specifically designed to treat distal colitis by direct mucosal contact 1, 2
- Suppositories are effective for proctitis, which is inflammation limited to a short distance from the anal verge 8